![](/wp-content/uploads/2018/10/9TJZeOAKRZeYjqZEByOa.png)
$599
AZ Provides Additional DAPA-CKD Commentary During Post-Results Investor Call
Following the DAPA-CKD results, which were presented at ESC 2020 on August 30 (previous FENIX insight), AZ hosted a call with investors (view slides here). Beyond reviewing the DAPA-CKD results, AZ senior management and DAPA-CKD investigators provided commentary on the trial results and the new Farxiga market potential. Below, FENIX provides highlights from the investor call as well as additional perspective on the impact of DAPA-CKD.